Comparison of primary and metastatic site‐related PD‐L1 expression in predicting ORR in patients with advanced NSCLC who received ICB‐based therapy

Autor: Danhong Zhou, Yang Wang, Weiwei Ning, Cheng Chen
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Thoracic Cancer, Vol 15, Iss 5, Pp 379-385 (2024)
Druh dokumentu: article
ISSN: 1759-7714
1759-7706
DOI: 10.1111/1759-7714.15201
Popis: Abstract Background Whether the value of PD‐L1 expression from metastatic sites to predict the efficacy of immune checkpoint blockade (ICB)‐based treatment is equivalent to that from a primary tumor is uncertain. This study aimed to compare the utility of PD‐L1 TPS from a primary lung tumor and metastatic sites to predict the overall response rate (ORR) of first‐line ICB‐based treatment. Methods This study included 249 patients with advanced non‐small cell lung cancer (NSCLC) who received first‐line ICB‐based treatment. All subjects underwent PD‐L1 testing prior to ICB‐based treatment and were divided into two cohorts corresponding to the different biopsy sites: lung primary site‐sampled cohort (PT cohort, n = 167) and metastatic site‐sampled cohort (MT cohort, n = 82). Results There was no statistical significance in PD‐L1 TPS distribution between the two cohorts (p = 0.742). PD‐L1 TPS ≥50% was also related to high ORR compared with PD‐L1
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje